title: Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
abstract: OBJECTIVE
  The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin's lymphoma (NHL).
  
  
  METHODS
  One hundred and thirteen consecutive patients with previously untreated aggressive NHL (diffuse large B-cell lymphoma, 96; peripheral T-cell lymphoma, 17) prospectively participated in this study between 1995 and 2001. The patients were treated with 6-8 cycles of a CHOP or THP (pirarubicin)-COP regimen.
  
  
  RESULTS
  A high serum sIL-2R level (2,000 U/ml and over) at onset was associated with a low complete remission rate. Patients with high sIL-2R had significantly lower survival rates (5-year, 24%) than those with low sIL-2R (under 2,000 U/ml) (74%) (P<0.01). Multivariate analysis employing sIL-2R levels and conventional prognostic factors demonstrated that high sIL-2R, presence of B-symptoms, and advanced age (60 years and older) were significantly unfavorable variables for overall survival. In addition, we attempted to use sIL-2R in combination with the International Prognostic Index (IPI). The patients in the high (H) risk group and those with high sIL-2R in the low-intermediate (LI)/high-intermediate (HI) risk group had significantly lower survival rates than the patients in the low (L) risk group and those with low sIL-2R in the LI/HI risk group (P<0.001).
  
  
  CONCLUSIONS
  The results suggest that a high serum sIL-2R level predicts a poor prognosis in aggressive NHL and may be a useful biomarker for selecting appropriate treatment when used in combination with the IPI.
authors.affiliation: First Department of Internal Medicine, Gifu University Graduate School of Medicine, 1-1 Yanagido, 501-1194 Gifu, Japan.
authors.forename: Hideko
authors.initials: H
authors.lastname: Goto
authors.forename: Hisashi
authors.initials: H
authors.lastname: Tsurumi
authors.forename: Masao
authors.initials: M
authors.lastname: Takemura
authors.forename: Yoriko
authors.initials: Y
authors.lastname: Ino-Shimomura
authors.forename: Senji
authors.initials: S
authors.lastname: Kasahara
authors.forename: Michio
authors.initials: M
authors.lastname: Sawada
authors.forename: Toshiki
authors.initials: T
authors.lastname: Yamada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hara
authors.forename: Kenji
authors.initials: K
authors.lastname: Fukuno
authors.forename: Naoe
authors.initials: N
authors.lastname: Goto
authors.forename: Masataka
authors.initials: M
authors.lastname: Okuno
authors.forename: Tsuyoshi
authors.initials: T
authors.lastname: Takami
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Seishima
authors.forename: Hisataka
authors.initials: H
authors.lastname: Moriwaki
mesh_terms: D000367:Age Factors; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis*; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology*; D016411:Lymphoma, T-Cell, Peripheral / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011379:Prognosis; D011446:Prospective Studies; D015375:Receptors, Interleukin-2 / Q000097:blood* / Q000737:chemistry; D012307:Risk Factors; D012995:Solubility; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D015375:Receptors, Interleukin-2